In 14 November 2005 Lux Biotechnology announced that Jim Brown, the exiting senior executive of GE Healthcare, was joining the company as chairman of the board of directors
Lux is a specialist developer of luminescent and fluorescent technologies.
Lux's product range includes reagents, bioassays, devices, and certified reference materials.
The company's strategy is to combine its proprietary bioassay technology and light reporter systems for a variety of applications including drug discovery, research tools, toxicity testing, and diagnostics.
As Lux moves toward expanding its operations Ian Sword, former chairman of the board, is leaving the company in mutual agreement.
Ian Sword said: "Lux biotech has a strong range of technologies and they have a bright future ahead of them.
"I am delighted that Dr Brown is joining the team.
"His strong industry experience will help Lux through its next stage of growth by successfully placing its technologies in the market".
Brown's career spans 35 years of prolific research and senior executive positions in pharmaceutical and biotech industry - Inveresk Research, Bioreliance, Mangenta Biotech, Amersham and finally as president of GE Healthcare.
He is also a founder member of both Bio in the USA and UK Bioindustry Association.
Brown is retiring from his position at GE Healthcare but will continue working with a number of companies at senior level.
Brown stated: "I am proud to be invited to become the new chairman of Lux Biotechnology.
"I am a scot who has benefited from my heritage, and an education which has allowed me to have a successful International career.
"At this point in my life, I wish use my experience to assist exciting young companies, such as Lux to establish their technologies in the world market.
"The handover from Ian Sword is seamless and logical.
"Ian has been a mentor to me over the years and was the person who gave me my first opportunity in business at Inveresk Research International in 1985 after 20 years as an MRC scientist in tropical medicine.
"He has done a great deal for the health science and biotech industries not only in Scotland but worldwide.
"I will strive to live up to the faith he has shown in me by asking me to take over his mantle.
"It will take some time for me to gain the same level of knowledge of Lux Biotechnology.
"I see my job as first, to ensure the good corporate governance of the company and to always make sure that the best interests of the shareholders and the staff are the top priorities.
"I will do my utmost to support the management team in a positive manner which is based on logic, questioning and mutual understanding.
"I will be independent and will make myself available to shareholders whenever necessary.
"The company has excellent technology which the global bioscience and health science industries need.
"The rationale for my appointment to the board is that the company believes that I can assist in taking Lux to the next steps by securing international recognition and acceptance of its developments".
